Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$12.24
-3.9%
$13.76
$8.66
$19.14
$1.69B1.551.62 million shs1.34 million shs
AtriCure, Inc. stock logo
ATRC
AtriCure
$22.61
-1.9%
$30.02
$22.07
$59.61
$1.09B1.38677,749 shs326,838 shs
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$28.41
-3.3%
$35.67
$27.18
$56.41
$2.23B1.12705,624 shs1.58 million shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-3.92%-0.81%-8.72%-24.68%-17.74%
AtriCure, Inc. stock logo
ATRC
AtriCure
-1.91%-3.33%-22.28%-32.00%-46.49%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
-3.30%-10.18%-15.82%-32.10%-47.58%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-6.93%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
4.051 of 5 stars
3.51.00.03.31.85.00.6
AtriCure, Inc. stock logo
ATRC
AtriCure
1.6951 of 5 stars
3.51.00.00.01.82.50.6
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
4.9122 of 5 stars
3.15.00.04.02.91.73.8
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
3.00
Buy$23.6393.01% Upside
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$52.63132.75% Upside
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
2.22
Hold$44.8958.00% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside

Current Analyst Ratings

Latest NUVA, ATRC, IART, and ATEC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$32.00
4/10/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00
4/3/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$38.00
3/28/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$22.00 ➝ $23.00
3/20/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
3/20/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $22.00
3/4/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/1/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$46.00 ➝ $41.00
2/29/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$55.00 ➝ $49.00
2/28/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $58.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$482.26M3.50N/AN/A$0.57 per share21.47
AtriCure, Inc. stock logo
ATRC
AtriCure
$399.24M2.74N/AN/A$9.84 per share2.30
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$1.54B1.45$4.67 per share6.09$20.31 per share1.40
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$186.64M-$1.55N/AN/AN/A-38.70%N/A-27.93%5/7/2024 (Confirmed)
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.66N/AN/AN/A-7.62%-7.55%-5.83%5/1/2024 (Confirmed)
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$67.74M$0.8334.237.870.884.39%15.19%6.59%5/6/2024 (Confirmed)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A

Latest NUVA, ATRC, IART, and ATEC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$0.33N/A+$0.33N/AN/AN/A  
5/6/2024N/A
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.55N/A-$0.55N/AN/AN/A  
5/1/2024N/A
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.20N/A+$0.20N/AN/AN/A  
2/28/202412/31/2023
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.90$0.89-$0.01$1.53$399.30 million$397.00 million    
2/27/2024Q4 2023
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$0.28-$0.37-$0.09-$0.37$131.90 million$138.00 million    
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
N/AN/AN/AN/AN/A
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
6.54
2.86
1.99
AtriCure, Inc. stock logo
ATRC
AtriCure
0.15
3.57
2.66
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
0.94
3.45
2.18
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
66.35%
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
84.78%
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A

Insider Ownership

CompanyInsider Ownership
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
29.12%
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3.10%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
839137.98 million97.80 millionOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20048.38 million46.83 millionOptionable
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3,94678.60 million76.17 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable

NUVA, ATRC, IART, and ATEC Headlines

SourceHeadline
Bone Void Fillers Market Size, Share, Key Players, Revenue, Demand, and Forecast to 2024 to 2032Bone Void Fillers Market Size, Share, Key Players, Revenue, Demand, and Forecast to 2024 to 2032
taiwannews.com.tw - April 19 at 1:56 AM
Regenerative Medicine Market Will Grow Nearly USD 194.9 Billion At A Rate Of 19.4% By 2032Regenerative Medicine Market Will Grow Nearly USD 194.9 Billion At A Rate Of 19.4% By 2032
pharmiweb.com - April 18 at 10:34 AM
SMAIO Publishes its 2023 Annual ResultsSMAIO Publishes its 2023 Annual Results
finance.yahoo.com - April 17 at 6:36 PM
This Week in Chancery Court: Poison Pill Ruling, NuVasiveThis Week in Chancery Court: Poison Pill Ruling, NuVasive
news.bloomberglaw.com - April 15 at 8:58 AM
Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032
taiwannews.com.tw - April 12 at 7:59 AM
10 robots used in spine surgery10 robots used in spine surgery
beckersspine.com - April 10 at 6:27 PM
Global Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market PlayersGlobal Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market Players
finance.yahoo.com - April 9 at 10:20 AM
Accelus adds 2 leadersAccelus adds 2 leaders
beckersspine.com - April 3 at 3:20 PM
$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028
finance.yahoo.com - April 3 at 10:19 AM
Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%
fmiblog.com - April 2 at 2:16 PM
Globus Medical director sells $550K in stockGlobus Medical director sells $550K in stock
beckersspine.com - March 20 at 4:48 PM
Orthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGROrthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGR
pharmiweb.com - March 14 at 9:11 AM
Wrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.usWrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.us
pharmiweb.com - March 13 at 10:23 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™
prnewswire.co.uk - March 13 at 10:23 PM
UK reinstates modified MAGEC X system for scoliosis treatmentsUK reinstates modified MAGEC X system for scoliosis treatments
msn.com - March 13 at 5:22 PM
Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033
pharmiweb.com - March 12 at 4:16 PM
Orthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust GrowthOrthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust Growth
finance.yahoo.com - March 12 at 4:16 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarketsMinimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets
finanznachrichten.de - March 12 at 9:26 AM
NuVasive and Zimmer Biomet welcomed by MedAccred programNuVasive and Zimmer Biomet welcomed by MedAccred program
medicalplasticsnews.com - March 6 at 4:00 PM
J. Kurt Jacobus, Ph.D. Joins CurvaFix Board of DirectorsJ. Kurt Jacobus, Ph.D. Joins CurvaFix Board of Directors
finance.yahoo.com - March 5 at 2:31 PM
Crushed Great Ormond Street hospital patients left in limbo after treatment axedCrushed Great Ormond Street hospital patients 'left in limbo' after treatment axed
express.co.uk - February 22 at 9:18 AM
Great Ormond Street patient cant get MAGEC spine operationGreat Ormond Street patient can't get MAGEC spine operation
newsshopper.co.uk - February 22 at 12:47 AM
Q4 2023 Globus Medical Inc Earnings CallQ4 2023 Globus Medical Inc Earnings Call
uk.finance.yahoo.com - February 21 at 2:46 PM
Globus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration RisksGlobus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration Risks
markets.businessinsider.com - February 21 at 2:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alphatec logo

Alphatec

NASDAQ:ATEC
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Integra LifeSciences logo

Integra LifeSciences

NASDAQ:IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.